Navigation Links
Using fMRI to study brain development
Date:11/30/2007

Functional magnetic resonance imaging (fMRI) is a powerful noninvasive tool for studying brain activity in both humans and experimental animals. Most fMRI studies are carried out on adults, but this technique also has great potential for studying early brain development. That potential is hampered, however, by a lack of knowledge about the basis of the fMRI signal in the developing brain. Now, by studying rats, MIT neuroscientists show that the fMRI signal changes during first few weeks of life. By correcting for those changes, the researchers were able to monitor the development of the rat brain. Determining whether analogous changes occur in humans will be important for interpreting developmental fMRI studies in young children.

Our study lays a foundation for using fMRI to study development, explains senior author Alan Jasanoff, Associate Member of the McGovern Institute and Assistant Professor of Nuclear Science and Engineering . It establishes an approach that others can apply to investigate many aspects of neurodevelopment in very young animals. Jasanoff collaborated with the lab of developmental biologist Martha Constantine-Paton, a McGovern Institute Principal Investigator. The study was published online November 25, in the journal Nature Neuroscience.

A fundamental difficulty in interpreting fMRI is that it provides only an indirect readout of brain activity, based on changes in the brains blood supply. Increases in brain activity cause increased blood flow, but the coupling mechanism that links these two processes is itself subject to change in early life. Thus, a weak fMRI signal in young animals could mean less neural activity, or it could simply mean that MRI cannot detect that activity because of weak neurovascular coupling.

To resolve this uncertainty, Jasanoff and colleagues compared fMRI signals with direct electrical recordings of neuronal activity as they stimulated rats forepaws. In animals younger than 11 days, th
'/>"/>

Contact: Charles Jennings
charlesj@mit.edu
617-324-3977
McGovern Institute for Brain Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Fever causing headaches for Aussie parents
3. Using evolution, UW team creates a template for many new therapeutic agents
4. Using green chemistry to deliver cutting-edge drugs
5. IGERT fellows to design biodevices using flexible electronics
6. Prediction of RNA pseudoknots using heuristic modeling with mapping and sequential folding
7. Computer program traces ancestry using anonymous DNA samples
8. Using nanotubes to detect and repair cracks in aircraft wings, other structures
9. Book on weeds and invasive plants discusses how to manage them using ecological approaches
10. Study shows housing development on the rise near national forests
11. Rare cancer-causing syndrome found, for the first time, in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)PHILADELPHIA People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smo
(Date:12/2/2009)PHILADELPHIA Exposure to secondhand smoke for a prolonged period of time and in high quantity may increase the risk of breast cancer, even in women who never smoked cigarettes themselves. , "The qu
(Date:12/2/2009)WEST LAFAYETTE, Ind. ╤ A Smoky Mountain forest,s woodland herb population has shown that climate may play a role in how forest understories recover from logging, according to Purdue University r
Breaking Biology News(10 mins):Increased nicotine levels detected in those who light-up earlier 2Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2Study finds logging effects vary based on a forest's history, climate 2Daily dose of color may boost immunity this flu season 60636 1Daily dose of color may boost immunity this flu season 60636 2MSU researcher 3A Obesity significantly cuts odds of successful pregnancy 10619 1MSU researcher 3A Obesity significantly cuts odds of successful pregnancy 10619 2UIC receives 241 million grant to study fat taxes diet obesity 10615 1UIC receives 241 million grant to study fat taxes diet obesity 10615 2
... not-for-profit publisher RSC Publishing announced... a new publication, Energy & Environmental Science...e will link all aspects of the chemical sciences b...n and storage, alternative fuel technologies, and ...l publishing topical reviews and original research...
... University of Toronto scientists have devised a t...cell by successfully mapping all 70,000 nucleosome...sformed into proteins and are critical indicators ...islow, a U of T Assistant Professor with the Banti...artment of Molecular Genetics, the team created a ...
...nosis of the temper and vital signs of the oceans ..., says a distinguished partnership of internationa...rine monitoring system within 10 years. , The Par...O) says warming seas, over-fishing and pollution a...sured to help society respond in a well-informed, ...
Other Biology News:Human safety, prosperity depend on better ocean observing system: Scientists 2Human safety, prosperity depend on better ocean observing system: Scientists 3Human safety, prosperity depend on better ocean observing system: Scientists 4Human safety, prosperity depend on better ocean observing system: Scientists 5Human safety, prosperity depend on better ocean observing system: Scientists 6Human safety, prosperity depend on better ocean observing system: Scientists 7Human safety, prosperity depend on better ocean observing system: Scientists 8
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...Md., Oct. 28 Novavax, Inc.,(Nasdaq: NVAX ) a cli...Dr.,Rahul Singhvi, President and Chief Executive O...um 2008 at 8:30 am. (PT) on October 30, 2008 at th...inghvi will provide an,overview of the company,s s... to the live presentation can be accessed via the ...
...Mass., Oct. 28 Peptimmune, Inc., a privately,held...dent & CEO Thomas P.,Mathers will provide an updat... for PI-2301 in multiple sclerosis patients at the...008. The presentation will take place on Wednesday...om at the Palace Hotel in San Francisco. 2. O...
...British Columbia, Oct. 28 ,ProtoKinetix Inc. (OTC ...n,the research, development and commercialization ...announced today that OTC Financial Network,(OTCFN)...Corp. (NFC), has,issued a corporate profile on the... ProtoKinetix technology platform, its multiple co...
Other Biology Technology:Peptimmune Presentations at Upcoming Events 2OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc. 2OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc. 3
...bulizers are available in two product models - the... two models is that the 6000AT+ includes a membran... aerosol for improved detection limits and reduced...on limits for a range of elements by 10-40 times. ...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related ...ailability of new radiolabeled ligands selected to...s a wide range of products and services for recept... state-of-the-art radioligands. If you do not find...
AMV RT HC 600 U from Invitrogen
...ding) was developed using a protein engineering ap... DNA binding pocket of wild-type DNase I. These ch...n for DNA. The result is a versatile enzyme that h...intain at least 50% of peak activity in solutions ...
Biology Products: